We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | NASDAQ:CMPI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.50 | 10.50 | 10.50 | 0 | 01:00:00 |
From Jul 2021 to Jul 2024
By Colin Kellaher
Shares of Checkmate Pharmaceuticals Inc. more than quadrupled in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by Regeneron Pharmaceuticals Inc. for about $250 million.
Regeneron is paying $10.50 a share in cash for Checkmate, more than four times Monday's closing price of $2.41 for the Cambridge, Mass., company and more than 30% above the stock's 52-week high of $7.97 reached last May.
The deal is slated to close by mid-year.
Checkmate shares were recently changing hands at $10.40, up 332%, in premarket trading, while Regeneron shares slipped 0.4% to $720.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 19, 2022 09:31 ET (13:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Checkmate Pharmaceuticals Chart |
1 Month Checkmate Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
